Core Viewpoint - Sichuan Huiyu Pharmaceutical Co., Ltd. has successfully completed the first administration of its innovative drug injection HY0001a in a Phase I clinical trial for treating advanced solid tumors [1][2]. Group 1: Drug Overview - Injection HY0001a is a first-class innovative biological product developed by the company's wholly-owned subsidiary, Huiyu Haiyue Pharmaceutical Technology Co., Ltd., aimed at treating advanced solid tumors [1][2]. - The clinical trial application for HY0001a was accepted by the National Medical Products Administration (NMPA) in April 2025, and the clinical trial approval notice was received in June 2025 [1]. Group 2: Research and Development Progress - Following the approval from NMPA, a multi-center, open-label Phase I/II clinical study has been initiated to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of HY0001a in patients with advanced malignant solid tumors [2]. - The main objectives of the study include assessing the safety and tolerability of HY0001a as a monotherapy, exploring the maximum tolerated dose (MTD), and providing recommended dosing for subsequent clinical studies [2]. - As of June 30, 2025, the cumulative R&D investment in this project is approximately RMB 60.10 million (unaudited) [2]. Group 3: Market Potential - Research indicates that CDCP1 is highly expressed in various cancers such as gastric, breast, lung, colorectal, and pancreatic cancers, making it an important target for ADC drug development [3]. - Preclinical studies have shown that HY0001a exhibits excellent anti-tumor effects and good safety profiles across multiple solid tumor models, indicating significant clinical development value [3].

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. has initiated a Phase I clinical trial for its self-developed innovative biological drug injection HY0001a, aimed at treating advanced solid tumors, with the first patient successfully dosed recently [1] Group 1: Product Development - Injection HY0001a is an antibody-drug conjugate classified as a Class 1 innovative therapeutic biological product [1] - As of the announcement date, there are no approved products targeting the same site in both domestic and international markets [1] Group 2: Research and Efficacy - Research indicates that CDCP1 is highly expressed in various tumors such as gastric cancer, breast cancer, lung cancer, colorectal cancer, and pancreatic cancer, while normal tissues show low or no expression, making it a significant potential target for ADC drug development [1] - Preclinical studies demonstrate that HY0001a exhibits excellent anti-tumor effects and good safety in multiple solid tumor models, indicating substantial clinical development value [1]

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., has initiated a Phase I clinical trial for its self-developed innovative biological drug, HY0001a, aimed at treating advanced solid tumors, with the first patient successfully dosed recently [1] Group 1 - HY0001a is an antibody-drug conjugate classified as a Class 1 innovative therapeutic biological product, with no approved products targeting the same site in both domestic and international markets as of the announcement date [1] - Research indicates that CDCP1 is highly expressed in various tumors such as gastric cancer, breast cancer, lung cancer, colorectal cancer, and pancreatic cancer, while normal tissues show low or no expression, making it a significant potential target for ADC drug development [1] - Preclinical studies demonstrate that HY0001a exhibits excellent anti-tumor effects and good safety in various solid tumor models, indicating substantial clinical development value [1]

Group 1 - Nanjing Weilizhibo Biotechnology Co., Ltd. officially listed on the Hong Kong Stock Exchange, becoming the third Nanjing company to go public this year, raising the total number of listed companies in Nanjing to 165 [1][2] - Weilizhibo focuses on the discovery, development, and commercialization of new therapies for tumors, autoimmune diseases, and other major diseases, with a pipeline of 12 products including monoclonal antibodies and antibody-drug conjugates [2][3] - The company has developed proprietary technology platforms such as LeadsBodyTM and X-bodyTM, which optimize the balance between efficacy and safety, aiming to improve patient quality of life [2][3] Group 2 - The company raised $189 million, which will be primarily used for clinical drug development, optimizing technology platforms, and increasing production capacity [3] - Weilizhibo has established a first-mover advantage in the solid tumor treatment market with a differentiated T-cell engager (TCE) product matrix covering hematological tumors, solid tumors, and autoimmune diseases [3] - Following Weilizhibo's listing, Nanjing's capital market is set to expand further with another company, Hansan (Nanjing) Technology Co., Ltd., expected to go public next month, increasing the total to 166 listed companies [4][5]

Group 1: Yimutian Inc. (一亩田) - Yimutian Inc. plans to go public on NASDAQ under the ticker "YMT" with an expected IPO date at the end of July 2023, aiming to raise up to $26 million by issuing 4.522 million American Depositary Shares (ADS) priced between $4.10 and $5.00 each [3][4] - Established in 2011, Yimutian has evolved from an information service platform to a comprehensive digital agriculture enterprise, serving over 56 million users and covering more than 340 cities and 2,800 counties in mainland China, capturing over 65% of the primary and secondary agricultural wholesale market [4] - The company has developed a new offline store model called "沃来采" to meet the needs of emerging buyers, leveraging its extensive buyer channels and market data to provide standardized and efficient agricultural brokerage services [4][5] Group 2: Weili Zhizhi Bio (维立志博) - Weili Zhizhi Bio officially listed on the Hong Kong Stock Exchange under the ticker "9887" on July 25, 2025, raising approximately HKD 1.29 billion by issuing 36,862,500 shares at an offer price of HKD 35.00 each [7][8] - The company attracted nine cornerstone investors, securing a total of USD 69 million (approximately HKD 541.6 million) in subscriptions, with notable contributions from firms like Tencent and various investment funds [8] - As a clinical-stage biotechnology company founded in 2012, Weili Zhizhi focuses on discovering and commercializing new therapies for cancer and autoimmune diseases, boasting a diverse product portfolio of 14 innovative candidates, including four core products that are leading in global clinical progress [9]

Core Viewpoint - The enthusiasm of mainland companies for listing on the Hong Kong stock market has surged, with 248 out of 450 companies planning to go public, indicating strong interest in the market [1] Company Overview - Founded in 2012, the company focuses on the discovery, development, and commercialization of new therapies for cancer and autoimmune diseases, positioning itself as a leader in next-generation cancer immunotherapy [3][4] - The company has completed 8 rounds of financing, raising a total of 1.084 billion yuan, attracting notable investors such as Enran Venture Capital and Shenzhen Capital Group [3] Product Pipeline - The company has developed 14 candidate drugs, with 6 currently in clinical stages, including its core product LBL-024, which is the first PD-L1/4-1BB bispecific antibody to enter the registration clinical phase globally [7][8] - LBL-024 is expected to become the fourth approved immunotherapy target after PD-1/L1, CTLA-4, and LAG3, with a significant market potential projected to reach $2.9 billion by 2030, growing at a CAGR of 284.9% from 2026 to 2030 [7] Clinical Progress - LBL-024 has received breakthrough therapy designation from the NMPA for treating advanced pulmonary neuroendocrine carcinoma and orphan drug designation from the FDA for neuroendocrine cancer, showcasing its clinical value and development potential [8] Strategic Positioning - The company has established a strong competitive barrier in the TCE field, having developed a proprietary LeadsBodyTM platform and a complete TCE product matrix covering hematological malignancies, solid tumors, and autoimmune diseases [9] - The innovative design of LBL-034, a bispecific TCE targeting GPRC5D and CD3, aims to activate T cells effectively while minimizing risks associated with T cell exhaustion and cytokine release syndrome [9] Innovation and Future Outlook - The company’s advancements in ADC, IO2.0, and TCE platforms highlight its robust research and development capabilities, contributing to a comprehensive innovation ecosystem [10][11] - The current IPO environment emphasizes the importance of companies with innovative potential and solid clinical data, reinforcing the market's focus on firms capable of sustained innovation and value realization [11]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 自願公告 於2025年AACR年會呈列的JSKN021及JSKN022的最新研究成果 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司統稱「本集團」）自願作 出，以知會本集團股東（「股東」）及潛在投資者有關本集團之最新業務進展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，JSKN021及JSKN022臨床前研究 的最新成果已於2025年4月25日至4月30日舉行的2025年AACR年會的壁報展示期 間（摘要展示編號：5450及5451）公佈。此研究結果概述如下。 JSKN021在臨床前研究中的藥理活性 背景：EGFR及HER3均屬於EGFR家族，在人類惡性腫瘤中廣泛過表達，使其成 為極具潛力的腫瘤治療靶點。腫瘤是一種異質性疾病，瘤間與瘤內的異質性被認 為是導致復發、轉移及對當前SO ...

Core Viewpoint - The collaboration between Shanghai Jinmant Biotech Co., Ltd. and Jiangsu Kangning Jereh Biopharmaceutical Co., Ltd. has led to the development of JSKN003, a targeted HER2 bispecific antibody-drug conjugate, which has received breakthrough therapy designation from the National Medical Products Administration of China for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer in the entire patient population [1][2]. Group 1 - Ovarian cancer ranks third in incidence among female reproductive system tumors in China and has the highest mortality rate among malignant tumors of the female reproductive tract, with approximately 70% of patients diagnosed at an advanced stage [1]. - Current treatment methods primarily involve tumor reduction surgery combined with postoperative platinum-based chemotherapy, but nearly all patients eventually develop platinum resistance [1]. - For platinum-resistant patients, non-platinum single-agent chemotherapy is the main treatment recommended by domestic and international guidelines, but its efficacy is limited, with low objective response rates (ORR) and short median progression-free survival (PFS) and overall survival [1]. Group 2 - Clinical studies of JSKN003 have shown preliminary efficacy breakthroughs in the specified indication, with good safety profiles and significant clinical advantages compared to existing treatment methods [1]. - The Phase III clinical trial for this indication is currently in the enrollment stage and is progressing smoothly [2]. - JSKN003 is also undergoing multiple Phase II and III clinical studies in China for the treatment of other solid tumors, including breast cancer, gastric cancer, colorectal cancer, and biliary tract cancer [2].

Core Viewpoint - The company has received breakthrough therapy designation from the National Medical Products Administration of China for JSKN 003, a targeted HER2 bispecific antibody-drug conjugate, aimed at treating platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer in all patient populations [1][4] Industry Summary - Ovarian cancer ranks as the third most common gynecological malignancy among women in China, with the highest mortality rate among female reproductive tract cancers, as approximately 70% of patients are diagnosed at an advanced stage [2] - Current treatment primarily involves tumor reduction surgery combined with postoperative platinum-based chemotherapy, but nearly all patients eventually develop resistance to platinum [2] - For platinum-resistant patients, non-platinum single-agent chemotherapy is the recommended treatment, but it has limited efficacy, with low objective response rates (ORR) and short median progression-free survival (PFS) and overall survival, indicating a significant unmet clinical need [2] Clinical Research Findings - A summary analysis of two clinical studies presented at the 2024 European Society for Medical Oncology (ESMO) annual meeting included 50 platinum-resistant participants treated with JSKN 003, showing an ORR of 56.8% and a disease control rate (DCR) of 95.5% [3] - Among 44 evaluable participants, 39 experienced tumor shrinkage, and the 6-month PFS rate was 44.7%, with HER2 expression levels influencing response rates [3] - The safety profile was favorable, with only 10% of participants experiencing grade 3 or higher treatment-related adverse events (TRAEs), and no treatment-related deaths reported [3] Ongoing Development - The Phase III clinical trial for this indication is currently in the enrollment stage and progressing smoothly [4] - JSKN 003 is also undergoing multiple Phase II and III clinical studies in China for the treatment of breast cancer, gastric cancer, colorectal cancer, and biliary tract cancer [4] - The breakthrough therapy designation is expected to expedite the development and review process, positioning JSKN 003 as a potential first-line anti-HER2 treatment for all platinum-resistant ovarian cancer patients [4]